clofibric acid has been researched along with dalcetrapib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kashyap, ML; Meyers, CD | 1 |
| Böhm, M; Laufs, U; Pöss, J | 1 |
2 review(s) available for clofibric acid and dalcetrapib
| Article | Year |
|---|---|
Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies.
Topics: Amides; Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Clofibric Acid; Esters; Glycoproteins; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Sulfhydryl Compounds; Thiazolidinediones | 2005 |
[HDL and CETP in atherogenesis].
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Nicotinic Acids; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome | 2010 |